mp.weixin.qq.com·· 11 hours agoScore75
Gilead to Acquire PepStar Oral IL-23R Program for $1.275 Billion Upfront in Cash
In brief
Gilead Sciences has announced an agreement to acquire PepStar Therapeutics' oral IL-23R inhibitor program for a $1.275 billion cash payment upfront, including the lead candidate HCXT-2001.
Source: mp.weixin.qq.com · mp.weixin.qq.com